Your new post is loading...
Research and publish the best content.
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Already have an account: Login
Vectorology - GEG Tech top picks
21.7K views |
+0 today
Editas Medicine said today its lead candidate EDIT-101, an in vivo CRISPR gene editing treatment for Leber congenital amaurosis-10 (LCA10), showed positive initial clinical data showing it to be safe, and to have generated "signals" of efficacy in two of three patients in the study’s adult mid-dose cohort.